Bharati Kochar1, Virginia Pate2, Michael D Kappelman3, Millie D Long4, Ashwin N Ananthakrishnan5, Andrew T Chan5, Robert S Sandler4. 1. Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts; Clinical Translational Epidemiology Unit, The Mongan Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: bkochar@mgh.harvard.edu. 2. The Sheps Center for Health Services Research, Chapel Hill, North Carolina. 3. Division of Pediatric Gastroenterology, Chapel Hill, North Carolina; Center for Gastrointestinal Disease and Biology, University of North Carolina, Chapel Hill, North Carolina. 4. Center for Gastrointestinal Disease and Biology, University of North Carolina, Chapel Hill, North Carolina; Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina. 5. Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts; Clinical Translational Epidemiology Unit, The Mongan Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND & AIMS: Despite the increased numbers of older adults with inflammatory bowel diseases (IBDs), there are few studies regarding the safety and effectiveness of IBD treatments in older adults. The aim of this study was to compare the safety and effectiveness of anti-tumor necrosis factor (TNF)-α agents and vedolizumab in older adults with IBD. METHODS: We conducted a retrospective cohort study using an active comparator, new-user design for adults age 65 years and older with IBD initiating anti-TNF-α agents and vedolizumab in the Medicare claims database from 2014 to 2017. The primary safety outcome was infection-related hospitalization (excluding intra-abdominal and perianal abscesses). Co-primary outcomes to estimate effectiveness were IBD-related hospitalization, IBD-related surgery, and new corticosteroid use 60 days or more after biologic initiation. We performed propensity score weighting to control for confounding and estimated adjusted hazard ratios and 95% confidence intervals using standardized morbidity ratio-weighted variables. RESULTS: We identified 1152 anti-TNF-α new users and 480 vedolizumab new users. The median age was 71 years in both cohorts and 11% were age 80 years or older. Crohn's disease patients comprised 54% of the anti-TNF-α cohort and 57% of the vedolizumab cohort. There was no significant difference in demographics, health care utilization, or frailty in both cohorts. More than half of both cohorts had a Charlson comorbidity index of 2 or higher. Vedolizumab users had a decreased risk of infection-related hospitalization (adjusted hazard ratio, 0.47; 95% confidence interval, 0.25-0.86). There was no significant difference in the outcomes approximating effectiveness. CONCLUSIONS: Older IBD patients treated with vedolizumab had a lower risk of infection-related hospitalization compared with those initiating anti-TNFs. We observed no difference in effectiveness defined by hospitalizations, surgery, or new corticosteroid use.
BACKGROUND & AIMS: Despite the increased numbers of older adults with inflammatory bowel diseases (IBDs), there are few studies regarding the safety and effectiveness of IBD treatments in older adults. The aim of this study was to compare the safety and effectiveness of anti-tumor necrosis factor (TNF)-α agents and vedolizumab in older adults with IBD. METHODS: We conducted a retrospective cohort study using an active comparator, new-user design for adults age 65 years and older with IBD initiating anti-TNF-α agents and vedolizumab in the Medicare claims database from 2014 to 2017. The primary safety outcome was infection-related hospitalization (excluding intra-abdominal and perianal abscesses). Co-primary outcomes to estimate effectiveness were IBD-related hospitalization, IBD-related surgery, and new corticosteroid use 60 days or more after biologic initiation. We performed propensity score weighting to control for confounding and estimated adjusted hazard ratios and 95% confidence intervals using standardized morbidity ratio-weighted variables. RESULTS: We identified 1152 anti-TNF-α new users and 480 vedolizumab new users. The median age was 71 years in both cohorts and 11% were age 80 years or older. Crohn's disease patients comprised 54% of the anti-TNF-α cohort and 57% of the vedolizumab cohort. There was no significant difference in demographics, health care utilization, or frailty in both cohorts. More than half of both cohorts had a Charlson comorbidity index of 2 or higher. Vedolizumab users had a decreased risk of infection-related hospitalization (adjusted hazard ratio, 0.47; 95% confidence interval, 0.25-0.86). There was no significant difference in the outcomes approximating effectiveness. CONCLUSIONS: Older IBD patients treated with vedolizumab had a lower risk of infection-related hospitalization compared with those initiating anti-TNFs. We observed no difference in effectiveness defined by hospitalizations, surgery, or new corticosteroid use.
Authors: Bruce E Sands; Laurent Peyrin-Biroulet; Edward V Loftus; Silvio Danese; Jean-Frédéric Colombel; Murat Törüner; Laimas Jonaitis; Brihad Abhyankar; Jingjing Chen; Raquel Rogers; Richard A Lirio; Jeffrey D Bornstein; Stefan Schreiber Journal: N Engl J Med Date: 2019-09-26 Impact factor: 91.245
Authors: Stephanie Coward; Fiona Clement; Eric I Benchimol; Charles N Bernstein; J Antonio Avina-Zubieta; Alain Bitton; Mathew W Carroll; Glen Hazlewood; Kevan Jacobson; Susan Jelinski; Rob Deardon; Jennifer L Jones; M Ellen Kuenzig; Desmond Leddin; Kerry A McBrien; Sanjay K Murthy; Geoffrey C Nguyen; Anthony R Otley; Remo Panaccione; Ali Rezaie; Greg Rosenfeld; Juan Nicolás Peña-Sánchez; Harminder Singh; Laura E Targownik; Gilaad G Kaplan Journal: Gastroenterology Date: 2019-01-10 Impact factor: 22.682
Authors: Carlos G Grijalva; Lang Chen; Elizabeth Delzell; John W Baddley; Timothy Beukelman; Kevin L Winthrop; Marie R Griffin; Lisa J Herrinton; Liyan Liu; Rita Ouellet-Hellstrom; Nivedita M Patkar; Daniel H Solomon; James D Lewis; Fenglong Xie; Kenneth G Saag; Jeffrey R Curtis Journal: JAMA Date: 2011-11-06 Impact factor: 56.272
Authors: Siddharth Singh; Herbert C Heien; Lindsey Sangaralingham; Nilay D Shah; Jennifer C Lai; William J Sandborn; Alison A Moore Journal: Inflamm Bowel Dis Date: 2021-10-18 Impact factor: 5.325
Authors: Matthew Bohm; Ronghui Xu; Yiran Zhang; Sashidhar Varma; Monika Fischer; Gursimran Kochhar; Brigid Boland; Siddharth Singh; Robert Hirten; Ryan Ungaro; Eugenia Shmidt; Karen Lasch; Vipul Jairaith; David Hudesman; Shannon Chang; Dana Lukin; Arun Swaminath; Bruce E Sands; Jean-Frederic Colombel; Sunanda Kane; Edward V Loftus; Bo Shen; Corey A Siegel; William J Sandborn; Parambir S Dulai Journal: Aliment Pharmacol Ther Date: 2020-07-13 Impact factor: 9.524